S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.15 (-1.65%)
BABA   73.99 (-1.19%)
AMD   121.39 (+0.19%)
T   16.76 (+1.15%)
F   10.58 (+3.12%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.36%)
GE   122.50 (+0.57%)
DIS   92.58 (-0.12%)
AMC   6.86 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.15 (-1.65%)
BABA   73.99 (-1.19%)
AMD   121.39 (+0.19%)
T   16.76 (+1.15%)
F   10.58 (+3.12%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.36%)
GE   122.50 (+0.57%)
DIS   92.58 (-0.12%)
AMC   6.86 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.15 (-1.65%)
BABA   73.99 (-1.19%)
AMD   121.39 (+0.19%)
T   16.76 (+1.15%)
F   10.58 (+3.12%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.36%)
GE   122.50 (+0.57%)
DIS   92.58 (-0.12%)
AMC   6.86 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.15 (-1.65%)
BABA   73.99 (-1.19%)
AMD   121.39 (+0.19%)
T   16.76 (+1.15%)
F   10.58 (+3.12%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.36%)
GE   122.50 (+0.57%)
DIS   92.58 (-0.12%)
AMC   6.86 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)

HLS Therapeutics Stock Price, News & Analysis (OTCMKTS:HLTRF)

$2.74
0.00 (0.00%)
(As of 11/30/2023 ET)
Compare
Today's Range
$2.74
$2.74
50-Day Range
$2.74
$3.84
52-Week Range
$2.60
$7.68
Volume
N/A
Average Volume
8,255 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.00

HLTRF stock logo

About HLS Therapeutics Stock (OTCMKTS:HLTRF)

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; Vascepa, an icosapent ethyl capsules for cardiovascular disease; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the United States marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

HLTRF Stock Price History

HLTRF Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
HLS Therapeutics Inc (HLS) Receives a Buy from Clarus
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
HLS Therapeutics earnings: here's what Wall Street expects
HLS Therapeutics Inc. (HLTRF)
HLS Therapeutics Inc. (TSE:HLS): When Will It Breakeven?
See More Headlines
Receive HLTRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:HLTRF
CIK
N/A
Fax
N/A
Employees
99
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.00
High Stock Price Target
$36.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+1,066.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Tim Hendrickson M.B.A. (Age 51)
    Chief Financial Officer
    Comp: $388.8k
  • Dr. Jason A. Gross Pharm.D. (Age 58)
    Vice President of Scientific Affairs
    Comp: $260.75k
  • Mr. Ryan C. Lennox B.A. (Age 42)
    J.D., Senior VP of Legal, HR & Compliance and Corporate Secretary
    Comp: $286.58k
  • Mr. Craig Stuart Millian M.B.A. (Age 55)
    CEO & Director
  • Brian T. Walsh
    Senior Vice President of Commercial
  • Mr. David Spence (Age 55)
    VP & Corporate Controller














HLTRF Stock Analysis - Frequently Asked Questions

Should I buy or sell HLS Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HLTRF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HLTRF, but not buy additional shares or sell existing shares.
View HLTRF analyst ratings
or view top-rated stocks.

What is HLS Therapeutics' stock price target for 2024?

1 brokerages have issued 12 month price targets for HLS Therapeutics' stock. Their HLTRF share price targets range from $28.00 to $36.00. On average, they anticipate the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 1,066.5% from the stock's current price.
View analysts price targets for HLTRF
or view top-rated stocks among Wall Street analysts.

How have HLTRF shares performed in 2023?

HLS Therapeutics' stock was trading at $7.25 at the beginning of 2023. Since then, HLTRF stock has decreased by 62.2% and is now trading at $2.7433.
View the best growth stocks for 2023 here
.

How do I buy shares of HLS Therapeutics?

Shares of HLTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:HLTRF) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -